Last edition
News about "Swedish Orphan Biovitrum AB"
Sobi-Innate Pharma Partnership Advances Lacutamab Phase 3 Study
The partnership between Sobi and Innate Pharma will support the TELLOMAK-3 confirmatory Phase 3 trial in CTCL and development of lacutamab in Sézary syndrome.
Swedish Orphan Biovitrum AB | 18/09/2026 | By News Bureau
Sobi and Innate Pharma Partner to Advance Lacutamab in T-Cell Lymphoma
Sobi and Innate Pharma partners to advance lacutamab into the TELLOMAK-3 Phase 3 trial, supporting its potential accelerated approval in Sézary syndrome and future development across cutaneous T-cell lymphoma.
Swedish Orphan Biovitrum AB | 10/08/2026 | By News Bureau | 127
Sobi has acquired Arthrosi Therapeutics, adding phase III gout candidate pozdeutinurad (AR882) to its portfolio, with trial results expected in 2026.
Swedish Orphan Biovitrum AB | 11/02/2026 | By News Bureau | 279
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy